The use of Cilostazol in Diabetic Patients
The International Diabetes Federation (IDF) reported that the global prevalence of diabetes (DM) in adults was 8.3% in 2013 expecting to rise beyond 592 million by 2035 with a 10.1% global prevalence [1]. Guidelines have been published for the treatment of this major disease and its complications [2...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
International Journal of Vascular Surgery and Medicine - Peertechz Publications,
2016-09-20.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_2455-5452_000014 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Konstantinos Spanos |e author |
| 700 | 1 | 0 | |a Athanasios D Giannoukas |e author |
| 245 | 0 | 0 | |a The use of Cilostazol in Diabetic Patients |
| 260 | |b International Journal of Vascular Surgery and Medicine - Peertechz Publications, |c 2016-09-20. | ||
| 520 | |a The International Diabetes Federation (IDF) reported that the global prevalence of diabetes (DM) in adults was 8.3% in 2013 expecting to rise beyond 592 million by 2035 with a 10.1% global prevalence [1]. Guidelines have been published for the treatment of this major disease and its complications [2,3]. Recently, cilostazol has been proposed for the treatment of diabetic patients and their complications. Cilostazol is a selective inhibitor of phosphodiesterase type 3 that appears to have both antiplatelet and anti-proliferative effects [4]. Cilostazol inhibits platelet aggregation in response to ADP, epinephrine, collagen and arachidonic acid, and suppresses the production of platelet derived endothelial cell growth factor [4]. | ||
| 540 | |a Copyright © Konstantinos Spanos et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Editorial |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/2455-5452.000014 |z Connect to this object online. |